Clinical trials: Higher-risk Myelodysplastic Syndrome
Myelodysplastic Syndrome, Acute Myeloblastic Leukemia
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
Association group of therapeutic specialities authorized in a remission induction treatment(FLAG-IDA: fludarabine, cytarabine, G-CSF (lenograstim) and idarubicin) and an intensive postremission treatment with authorized…
- Trial name
- FLAG-IDA (NCT00487448)
- Testing
- Fludarabine, Cytarabine, G-CSF
- Where
- 15 sites in Spain
- Volunteers
- 200 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
This is an open-label, single-center, non-randomized phase I/II pilot study evaluating proton-based Total Marrow Irradiation (TMI) as part of the conditioning regimen prior to allogeneic hematopoietic stem cell transplantation…
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Proton Therapy, MDS and AML Prior to Allogeneic SCT
- Trial name
- UHKT-PTC-TMI-1 (NCT07532824)
- Testing
- Proton Total Marrow Irradiation
- Where
- 2 sites in Czechia
- Volunteers
- 16 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Study CC-90002-AML-001 is an open-label, Phase 1 dose escalation (Part A) and expansion (Part B), clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with relapsed and/or primary refractory AML and…
- Trial name
- NCT02641002
- Testing
- CC-90002
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Celgene
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood (hematologic).
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, High Risk Myelodysplastic Syndrome
- Trial name
- NCT02530034
- Testing
- Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia
Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS
This is a single center, open label, random comparison phase 2b study. The primary objective of this study is, by random comparison, to assess the anti-leukemia effect of allogeneic, donor-derived natural killer (NK) cells…
- Trial name
- DNKI-4 (NCT02477787)
- Testing
- allogeneic, donor-derived NK cells
- Where
- South Korea
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Leukemia, Myeloid, Myelodysplastic Syndromes
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
The goal of this clinical research study is to learn if the combination of Gleevec (imatinib mesylate) and low doses of Cytarabine (ara-C) may help to control leukemia while causing fewer side effects than standard high dose…
- Trial name
- NCT00451997
- Testing
- Gleevec, Ara-C
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with azacitidine to patients with MDS or AML.
- Trial name
- NCT01038635
- Testing
- 5-Azacytidine, Lenalidomide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndrome (MDS)
Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome
The purpose of the study is to determine whether azacitidine is safe and effective in the treatment of Chinese patients with higher risk Myelodysplastic Syndromes (MDS).
- Trial name
- NCT01599325
- Testing
- Azacitidine
- Where
- 11 sites in China
- Volunteers
- 72 people
- Sponsor
- Celgene
Leukemia, Lymphoma
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002989
- Testing
- busulfan, cyclophosphamide, idarubicin
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 207 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.
- Trial name
- NCT06046313
- Testing
- Decitabine for Injection, VENCLYXTO
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of veliparib when given together with topotecan hydrochloride with or without carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk…
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT00588991
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndromes
COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
This faisability study aims to evaluate the adhesion of the patient to a multidisciplinary program (adapted physical activity, coaching and nutrition)
- Trial name
- COHABILIT (NCT03595787)
- Testing
- Coaching and Habilitation
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Paoli-Calmettes
Myelodysplastic Syndrome
Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation
The purpose of this study is to evaluate the feasibility and efficacy of reduced-intensity conditioning allogeneic HCT followed by prophylactic dose-escalating DLIs in patients with higher risk MDS.
- Trial name
- RICandDLI (NCT01252784)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Cooperative Study Group A for Hematology
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for…
- Trial name
- NCT04264806
- Testing
- Azacitidine, Cusatuzumab
- Where
- 73 sites in Australia, Brazil and 9 more
- Sponsor
- Janssen Research & Development, LLC
Myelodysplastic Syndromes
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk…
- Trial name
- ENHANCE (NCT04313881)
- Testing
- Magrolimab, Azacitidine
- Where
- 169 sites in United States, Australia and 19 more
- Volunteers
- 539 people
- Sponsor
- Gilead Sciences
Multiple Myeloma, Acute Myeloid Leukaemia
Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome
Patients with some forms of acute myeloid leukemia (AML) and multiple myeloma (MM) are not cured with conventional therapy and new approaches are needed.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukaemia, Myelodysplastic Syndrome
- Trial name
- NCT01716364
- Testing
- Anti-LeY- scFv-CD28-ζ vector,.
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Myelodysplastic Syndromes
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
- Trial name
- ImmBridge (NCT06918834)
- Testing
- Immediate HSCT Group, Bridging Therapy Group
- Where
- 5 sites in China
- Volunteers
- 236 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic…
- Trial name
- NCT01031498
- Testing
- Ondansetron, Palonosetron
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Malignancy, Hematologic Malignancy
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances with Fludarabine and Melphalan.
- Conditions
- Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT07044544
- Testing
- G-CSF, Decitabine, Venetoclax
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia.
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT05038592
- Testing
- Decitabine, Tagraxofusp-erzs
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center